Blood Test Determines Esophageal Cancer Patient Treatment Options
By LabMedica International staff writers Posted on 21 Oct 2014 |
Image: A fluorescent proximity ligation assay of protein-protein interactions (Photo courtesy of Abnova).
A blood test that may be beneficial in indicating neoadjuvant treatment regimens for patients with esophageal squamous cell carcinoma has been introduced.
The blood test measures levels of two proteins found in the body, vascular endothelial growth factor-A (VEGF-A) and transforming growth factor-β1 (TGF-β1), indicate patients’ pathological response, and disease-free survival rates.
Scientists at the National Taiwan University Hospital (Taipei City, Taiwan) evaluated serum samples of 103 total patients with esophageal squamous cell carcinoma (ESCC) from 2004 to 2013. All patients received preoperative taxane-/5-fluorouracil-based chemotherapy (CCRT) and 40 gray (Gy) dose of radiation therapy prior to esophagectomy, the surgical removal of a part of the esophagus.
Serum samples were collected from patients before and within one month of completion of CCRT. The team used a proximity ligation assay (PLA) technique to screen for 15 serum biomarkers in 79 patients to evaluate the biomarkers’ association with pathological tumor regression on surgery and survival. The biomarkers significantly associated with pathological response (PathR) and survival rates were further analyzed by traditional enzyme-linked, immunosorbent assay (ELISA) to confirm initial biomarker findings by PLA in the total group of 103 patients.
The investigators found that patients with high VEGF-A were less likely to achieve complete tumor regression or a decrease in the size of a tumor or in the extent of cancer in the body, and that the survival rates were lower among patients who had high VEGF-A and high TGF-β1 levels before treatment. On ELISA, both pre- and post-CCRT VEGF-A levels were significantly correlated with PathR. Patients with pretreatment VEGF-A of less than 250 pg/mL showed a statistically significant pathologically complete response after CCRT (57.1%, or 20/35) compared to patients with VEGF-A of more than 250 pg/mL (26.5% or 18/68).
Jason Cheng, MD, the senior author of the study said, “Through the utilization of a specific blood test of serum biomarkers, we could potentially predict if a patient will have a favorable pathological response and outcome before radiotherapy. Treatment could be tailored for patients in order to achieve better outcomes and/or fewer side effects. Our study showed that the serum levels of VEGF-A and TGF-β1 were significant only before treatment. This would allow us to individualize the neoadjuvant treatment regimens based on the pretreatment serum levels of VEGF-A and TGF-β1.” The study was presented on September 14, 2014, at the American Society for Radiation Oncology’s (ASTRO’s) 56th Annual Meeting, held in San Francisco (CA, USA).
Related Links:
National Taiwan University Hospital
The blood test measures levels of two proteins found in the body, vascular endothelial growth factor-A (VEGF-A) and transforming growth factor-β1 (TGF-β1), indicate patients’ pathological response, and disease-free survival rates.
Scientists at the National Taiwan University Hospital (Taipei City, Taiwan) evaluated serum samples of 103 total patients with esophageal squamous cell carcinoma (ESCC) from 2004 to 2013. All patients received preoperative taxane-/5-fluorouracil-based chemotherapy (CCRT) and 40 gray (Gy) dose of radiation therapy prior to esophagectomy, the surgical removal of a part of the esophagus.
Serum samples were collected from patients before and within one month of completion of CCRT. The team used a proximity ligation assay (PLA) technique to screen for 15 serum biomarkers in 79 patients to evaluate the biomarkers’ association with pathological tumor regression on surgery and survival. The biomarkers significantly associated with pathological response (PathR) and survival rates were further analyzed by traditional enzyme-linked, immunosorbent assay (ELISA) to confirm initial biomarker findings by PLA in the total group of 103 patients.
The investigators found that patients with high VEGF-A were less likely to achieve complete tumor regression or a decrease in the size of a tumor or in the extent of cancer in the body, and that the survival rates were lower among patients who had high VEGF-A and high TGF-β1 levels before treatment. On ELISA, both pre- and post-CCRT VEGF-A levels were significantly correlated with PathR. Patients with pretreatment VEGF-A of less than 250 pg/mL showed a statistically significant pathologically complete response after CCRT (57.1%, or 20/35) compared to patients with VEGF-A of more than 250 pg/mL (26.5% or 18/68).
Jason Cheng, MD, the senior author of the study said, “Through the utilization of a specific blood test of serum biomarkers, we could potentially predict if a patient will have a favorable pathological response and outcome before radiotherapy. Treatment could be tailored for patients in order to achieve better outcomes and/or fewer side effects. Our study showed that the serum levels of VEGF-A and TGF-β1 were significant only before treatment. This would allow us to individualize the neoadjuvant treatment regimens based on the pretreatment serum levels of VEGF-A and TGF-β1.” The study was presented on September 14, 2014, at the American Society for Radiation Oncology’s (ASTRO’s) 56th Annual Meeting, held in San Francisco (CA, USA).
Related Links:
National Taiwan University Hospital
Latest Immunology News
- AI Predicts Tumor-Killing Cells with High Accuracy
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form